MorphoSys (MPSYF) 6-K MorphoSys to Present Data on Tafasitamab at the ASCO and EHA Virtual Meetings

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM6-K

REPORT OF A FOREIGN ISSUER

PURSUANT TO RULE13A-16 OR15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For May 22, 2020

Commission File Number1-38455

MorphoSys AG

Semmelweisstrasse 7

82152 Planegg

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form20-F  ☒            Form40-F  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐            No  ☒

If ‘‘Yes’’ is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):            

Exhibits

99.1 MorphoSys to Present Data on Tafasitamab at the ASCO and EHA Virtual Meetings

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MORPHOSYS AG (Registrant)
Date: May 22, 2020	By:	/s/ Jens Holstein
	Name:	Jens Holstein
	Title:	CFO
	By:	/s/ Charlotte Lohmann
	Name:	Charlotte Lohmann
	Title:	General Counsel